{
    "clinical_study": {
        "@rank": "40029", 
        "acronym": "HEVRibavirin", 
        "arm_group": [
            {
                "arm_group_label": "Ribavirin", 
                "arm_group_type": "Active Comparator", 
                "description": "1000 mg (5 capsules)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "5 capsules of placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The term Acute on chronic liver failure (ACLF) describes a clinical entity characterized by\n      an acute and rapid deterioration of liver function in a patient with previously\n      well-compensated liver disease owing to the effects of a precipitating event. In this\n      condition two insults act simultaneously, one being the preexisting liver injury (chronic\n      liver disease) and the other acute injury which is responsible for the acute decompensation.\n      HEV being a major factor responsible for this clinical entity and has a very high mortality\n      rate. Ribavirin being a safe drug and has been shown to inhibit the replication of HEV, can\n      be an important drug in the treatment of these patients. Therefore the present study is\n      designed to study the impact of Ribavirin in reducing the mortality due to HEV related ACLF."
        }, 
        "brief_title": "A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute on Chronic Hepatic Failure", 
            "Liver Failure", 
            "Hepatitis E Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis E", 
                "Liver Failure", 
                "Liver Failure, Acute", 
                "End Stage Liver Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All ACLF due to HEV\n\n          -  Consent to participate in trial and collection of blood.\n\n        Exclusion Criteria:\n\n          -  Pregnant and nursing mothers.\n\n          -  Severe anemia\n\n          -  Other etiologies of ACLF (eg. Alcohol, drugs, reactivation of hepatitis B     and\n             hepatitis C, variceal bleeding, surgical intervention and sepsis)\n\n          -  Hepatocellular carcinoma (HCC)\n\n          -  Hepatorenal syndrome (HRS) at admission\n\n          -  Presence of life threatening cardiovascular, respiratory and neurological disease\n\n          -  Acquired Immunodeficiency Syndrome\n\n          -  Patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia)\n\n          -  Refusal to provide consent to participate in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698723", 
            "org_study_id": "HEV-RIBA"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ribavirin", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ACLF", 
            "HEV", 
            "Ribavirin"
        ], 
        "lastchanged_date": "September 29, 2012", 
        "location": [
            {
                "contact": {
                    "email": "subratacharya2004@yahoo.com", 
                    "last_name": "Subrat K Acharya, DM", 
                    "phone": "+91-11-26594934"
                }, 
                "contact_backup": {
                    "email": "drshalimar@yahoo.com", 
                    "last_name": "Shalimar ., DM", 
                    "phone": "+91-9968405815"
                }, 
                "facility": {
                    "address": {
                        "city": "Delhi", 
                        "country": "India", 
                        "zip": "110029"
                    }, 
                    "name": "AII India Institute of Medical Sciences"
                }, 
                "investigator": {
                    "last_name": "Subrat K Acharya, DM", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "subratacharya2004@yahoo.com", 
                    "last_name": "Subrat K Acharya, DM", 
                    "phone": "+91-11-26594934"
                }, 
                "contact_backup": {
                    "email": "drshalimar@yahoo.com", 
                    "last_name": "Shalimar ., DM", 
                    "phone": "+91-9968405815"
                }, 
                "facility": {
                    "address": {
                        "city": "Delhi", 
                        "country": "India", 
                        "zip": "110029"
                    }, 
                    "name": "All India Institute of Medical Sciences"
                }, 
                "investigator": {
                    "last_name": "Subrat K Acharya, DM", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double Blind Placebo Controlled Randomized Trial of Ribavirin in Patients With Acute on Chronic Liver Failure Due to Hepatitis E Virus", 
        "overall_contact": {
            "email": "subratacharya2004@yahoo.com", 
            "last_name": "Subrat K Acharya, DM", 
            "phone": "+91-11-26594934"
        }, 
        "overall_contact_backup": {
            "last_name": "Shalimar ., DM", 
            "phone": "+919968405815"
        }, 
        "overall_official": {
            "affiliation": "All India Institute of Medical Sciences, New Delhi", 
            "last_name": "Subrat K Acharya, DM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Improvement in survival", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks and 12 moths"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698723"
        }, 
        "responsible_party": {
            "investigator_affiliation": "All India Institute of Medical Sciences, New Delhi", 
            "investigator_full_name": "Subrat Kumar Acharya", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in Child Score will be evaluated at every 4 week interval", 
                "measure": "Child Score", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks and 12 months"
            }, 
            {
                "description": "Change in viral load", 
                "measure": "Viremia", 
                "safety_issue": "No", 
                "time_frame": "4 weeks, 3 months"
            }, 
            {
                "description": "Variceal bleeding will be assessed every 4 weeks", 
                "measure": "Variceal bleeding", 
                "safety_issue": "No", 
                "time_frame": "4 weeks and 12 months"
            }
        ], 
        "source": "All India Institute of Medical Sciences, New Delhi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "All India Institute of Medical Sciences, New Delhi", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}